95 related articles for article (PubMed ID: 17506942)
21. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats.
Soetikno V; Watanabe K; Sari FR; Harima M; Thandavarayan RA; Veeraveedu PT; Arozal W; Sukumaran V; Lakshmanan AP; Arumugam S; Suzuki K
Mol Nutr Food Res; 2011 Nov; 55(11):1655-65. PubMed ID: 22045654
[TBL] [Abstract][Full Text] [Related]
22. Different expressions of protein kinase C-alpha, beta I and beta II in glomeruli of diabetic nephropathy patients.
Yao L; Wang J; Mao Y; Zhu H; Deng A; Zhu Z
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):651-3. PubMed ID: 17357479
[TBL] [Abstract][Full Text] [Related]
23. Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
Rao RP; Jain A; Srinivasan B
J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):169-75. PubMed ID: 21421651
[TBL] [Abstract][Full Text] [Related]
24. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice.
Menne J; Park JK; Boehne M; Elger M; Lindschau C; Kirsch T; Meier M; Gueler F; Fiebeler A; Bahlmann FH; Leitges M; Haller H
Diabetes; 2004 Aug; 53(8):2101-9. PubMed ID: 15277392
[TBL] [Abstract][Full Text] [Related]
25. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan, a possible PPAR-δ agonist, reduces TNF-α-stimulated VEGF-C production by inhibiting the p38MAPK/HSP27 pathway in human proximal renal tubular cells.
Kimura H; Mikami D; Kamiyama K; Sugimoto H; Kasuno K; Takahashi N; Yoshida H; Iwano M
Biochem Biophys Res Commun; 2014 Nov; 454(2):320-7. PubMed ID: 25450396
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
28. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice.
Ohshiro Y; Ma RC; Yasuda Y; Hiraoka-Yamamoto J; Clermont AC; Isshiki K; Yagi K; Arikawa E; Kern TS; King GL
Diabetes; 2006 Nov; 55(11):3112-20. PubMed ID: 17065350
[TBL] [Abstract][Full Text] [Related]
29. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
30. Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers.
Onozato ML; Tojo A; Leiper J; Fujita T; Palm F; Wilcox CS
Diabetes; 2008 Jan; 57(1):172-80. PubMed ID: 17909098
[TBL] [Abstract][Full Text] [Related]
31. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.
Saitoh Y; Hongwei W; Ueno H; Mizuta M; Nakazato M
Diabetes Metab; 2009 Nov; 35(5):392-7. PubMed ID: 19713141
[TBL] [Abstract][Full Text] [Related]
32. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Fujita H; Fujishima H; Morii T; Sakamoto T; Komatsu K; Hosoba M; Narita T; Takahashi K; Takahashi T; Yamada Y
Hypertens Res; 2012 Feb; 35(2):213-20. PubMed ID: 22072110
[TBL] [Abstract][Full Text] [Related]
33. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
Clemenz M; Frost N; Schupp M; Caron S; Foryst-Ludwig A; Böhm C; Hartge M; Gust R; Staels B; Unger T; Kintscher U
Diabetes; 2008 May; 57(5):1405-13. PubMed ID: 18184928
[TBL] [Abstract][Full Text] [Related]
34. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.
Soler MJ; Ye M; Wysocki J; William J; Lloveras J; Batlle D
Am J Physiol Renal Physiol; 2009 Feb; 296(2):F398-405. PubMed ID: 19004932
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor.
Usui T; Sugisaki K; Iriyama A; Yokoo S; Yamagami S; Nagai N; Ishida S; Amano S
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4370-6. PubMed ID: 18829859
[TBL] [Abstract][Full Text] [Related]
36. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
Mulay SR; Gaikwad AB; Tikoo K
Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228
[TBL] [Abstract][Full Text] [Related]
37. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
38. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
Ott IM; Alter ML; von Websky K; Kretschmer A; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Stasch JP; Hocher B
PLoS One; 2012; 7(8):e42623. PubMed ID: 22900035
[TBL] [Abstract][Full Text] [Related]
39. Quercetin ameliorates diabetic nephropathy by reducing the expressions of transforming growth factor-β1 and connective tissue growth factor in streptozotocin-induced diabetic rats.
Lai PB; Zhang L; Yang LY
Ren Fail; 2012; 34(1):83-7. PubMed ID: 22011322
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
